Study results pending publication in July print edition of Clinical
Chemistry, available on Web
INDIANAPOLIS, July 23 /PRNewswire/ -- A Roche Diagnostics-sponsored pilot study evaluating the use of N-terminal pro-B-type natriuretic peptide (NT-proBNP) confirms the potential value of NT-proBNP for risk stratification in predicting the risk of cardiovascular adverse events (CV-AE) in patients treated with non-steroidal anti-inflammatory drugs of the COX inhibitor class.
The complete results of the study, currently available at http://www.clinchem.org , are scheduled for publication in the July print edition of Clinical Chemistry.
Non-steroidal anti-inflammatory drugs (NSAIDs) -- for example, acetylsalicylic acid and ibuprofen -- are the best known inhibitors of COX (cyclo-oxygenase), an enzyme involved in the inflammation pathway. This inhibition provides relief from the symptoms of the inflammation process; for example, fever and pain.
These drugs are routinely used to treat patients with osteoarthritis, rheumatoid arthritis and other pathologies associated with inflammation. However, studies with newer NSAIDs such as the selective COX-2 inhibitors (also called coxibs) have resulted in concern that there might be an increase in the risk of heart attack, thrombosis or stroke associated with long-term, high-dosage use of coxibs. Traditional NSAIDs (tNSAIDs) demonstrate comparable risks in observational studies.
Cardiovascular risk could be predicted
A pilot study(1) examined whether the risk of CV-AE could be predicted by measuring the NT-proBNP concentration in patients taking anti-inflammatory drugs. Baseline samples were measured by Elecsys proBNP (Roche Diagnostics) in 433 patients with osteoarthritis of the knees, with or without osteoarthritis of the hands, during an observational period of 200 days.
Cardiovascular adverse events -
|SOURCE Roche Diagnostics|
Copyright©2008 PR Newswire.
All rights reserved